Literature DB >> 29989668

Burosumab: At Long Last, an Effective Treatment for FGF23-Associated Hypophosphatemia.

Michael Collins1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29989668     DOI： 10.1002/jbmr.3544

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN： 0884-0431            Impact factor:   6.741


× No keyword cloud information.
  9 in total

Review 1.  Congenital Conditions of Hypophosphatemia Expressed in Adults.

Authors:  Gemma Marcucci; Maria Luisa Brandi
Journal:  Calcif Tissue Int       Date:  2020-05-14       Impact factor: 4.333

Review 2.  FGF23 and Associated Disorders of Phosphate Wasting.

Authors:  Anisha Gohil; Erik A Imel
Journal:  Pediatr Endocrinol Rev       Date:  2019-09

Review 3.  New concepts in regulation and function of the FGF23.

Authors:  Sanaz Dastghaib; Farhad Koohpeyma; Mesbah Shams; Forough Saki; Aliakbar Alizadeh
Journal:  Clin Exp Med       Date:  2022-06-16       Impact factor: 3.984

4.  Congenital hypophosphataemia in adults: determinants of bone turnover markers and amelioration of renal phosphate wasting following total parathyroidectomy.

Authors:  Malachi J McKenna; Julie Martin-Grace; Rachel Crowley; Patrick J Twomey; Mark T Kilbane
Journal:  J Bone Miner Metab       Date:  2018-09-20       Impact factor: 2.626

Review 5.  Burosumab for Pediatric X-Linked Hypophosphatemia.

Authors:  Erik A Imel
Journal:  Curr Osteoporos Rep       Date:  2021-05-10       Impact factor: 5.163

6.  Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review.

Authors:  L Seefried; M Smyth; R Keen; P Harvengt
Journal:  Osteoporos Int       Date:  2020-07-24       Impact factor: 4.507

7.  Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia.

Authors:  Raja Padidela; Michael P Whyte; Francis H Glorieux; Craig F Munns; Leanne M Ward; Ola Nilsson; Anthony A Portale; Jill H Simmons; Noriyuki Namba; Hae Il Cheong; Pisit Pitukcheewanont; Etienne Sochett; Wolfgang Högler; Koji Muroya; Hiroyuki Tanaka; Gary S Gottesman; Andrew Biggin; Farzana Perwad; Angela Williams; Annabel Nixon; Wei Sun; Angel Chen; Alison Skrinar; Erik A Imel
Journal:  Calcif Tissue Int       Date:  2021-01-23       Impact factor: 4.333

8.  A novel therapeutic strategy for skeletal disorders: Proof of concept of gene therapy for X-linked hypophosphatemia.

Authors:  Volha V Zhukouskaya; Louisa Jauze; Séverine Charles; Christian Leborgne; Stéphane Hilliquin; Jérémy Sadoine; Lotfi Slimani; Brigitte Baroukh; Laetitia van Wittenberghe; Natalie Danièle; Fabienne Rajas; Agnès Linglart; Federico Mingozzi; Catherine Chaussain; Claire Bardet; Giuseppe Ronzitti
Journal:  Sci Adv       Date:  2021-10-27       Impact factor: 14.136

9.  An Expert Perspective on Phosphate Dysregulation With a Focus on Chronic Hypophosphatemia.

Authors:  Fahad Aljuraibah; Justine Bacchetta; Maria Luisa Brandi; Pablo Florenzano; Muhammad K Javaid; Outimaija Mäkitie; Adalbert Raimann; Mariano Rodriguez; Heide Siggelkow; Dov Tiosano; Marc Vervloet; Carsten A Wagner
Journal:  J Bone Miner Res       Date:  2021-12-23       Impact factor: 6.390
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.